{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:27:34Z","timestamp":1754144854209,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>To elucidate the role of transcriptional regulators (TRs) associated with invasiveness in multiple myeloma (MM), we conducted a systematic network analysis to identify key master regulators (MRs) that govern MM invasiveness. We employed a consensus clustering method based on a 24-gene signature to classify MM patients into high invasiveness (INV-H) and low invasiveness (INV-L) groups. Subsequently, we identified TRs specific to the INV-H and INV-L phenotypes as MRs using a network-based approach, and we validated the MR activities that correlated with the INV-H phenotype across multiple independent datasets. We evaluated the effect of MRs on patient outcomes in relation to the prognosis of MM. By utilizing siRNA to disrupt ERG expression in U266 and RPMI8226 cell lines, we evaluated the effects of the master regulator ERG on the proliferation, apoptosis, invasion, and migration of myeloma cell lines, and we confirmed the expression of ERG in patients with extramedullary MM. We assessed invasiveness using a 24-gene signature, categorizing patients into INV-H and INV-L groups. Our network identified MRs linked to MM invasiveness and revealed enriched signaling pathways. High ERG expression correlated with poor prognosis. ERG silencing reduced cell invasiveness, migration, and apoptosis, while promoting proliferation. Elevated ERG was found in extramedullary MM, and potential drug candidates, including Idarubicin, were identified for treatment. This study provides a comprehensive analysis of master regulators in EMM, contributing to targeted therapeutic strategies. We identified ERG as a marker for extramedullary invasion in MM, suggesting it as a potential therapeutic target for future interventions.<\/jats:p>","DOI":"10.3389\/fcell.2025.1586870","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:39:12Z","timestamp":1752644352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Network analysis of master regulators associated with invasive phenotypes in multiple myeloma"],"prefix":"10.3389","volume":"13","author":[{"given":"Feng","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood cancer J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12967-021-02773-x","article-title":"Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types","volume":"19","author":"Bi","year":"2021","journal-title":"J. Transl. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/jco.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6672","DOI":"10.1038\/s41467-024-50908-7","article-title":"Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer","volume":"15","author":"Cacciatore","year":"2024","journal-title":"Nat. Commun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc.2016.124","article-title":"The recurrent architecture of tumour initiation, progression and drug sensitivity","volume":"17","author":"Califano","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"B8","first-page":"159","article-title":"Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies","volume":"75","author":"Carella","year":"1990","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drudis.2021.09.007","article-title":"Machine-learning methods for ligand-protein molecular docking","volume":"27","author":"Crampon","year":"2022","journal-title":"Drug Discov. Today"},{"key":"B10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.eururo.2014.03.045","article-title":"TMPRSS:ERG fusion in prostate cancer: from experimental approaches to prognostic studies","volume":"66","author":"Culig","year":"2014","journal-title":"Eur. Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"720571","DOI":"10.3389\/fimmu.2021.720571","article-title":"Efficacy of humanized anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma patients with and without extramedullary disease","volume":"12","author":"Deng","year":"2021","journal-title":"Front. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.3928\/23258160-20191031-21","article-title":"Intraocular deposition of copper and ERG findings in a patient with progressive vision loss from hypercupremia","volume":"50","author":"Donovan","year":"2019","journal-title":"Ophthalmic Surg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/cancers16030498","article-title":"Novel insights into the initiation, evolution, and progression of multiple myeloma by multi-omics investigation","volume":"16","author":"Gong","year":"2024","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","article-title":"Targeting MYC in multiple myeloma","volume":"32","author":"Jovanovi\u0107","year":"2018","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.prp.2016.10.014","article-title":"ERG expression in multiple myeloma-A potential diagnostic pitfall","volume":"213","author":"Knief","year":"2017","journal-title":"Pathology, Res. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1093\/bioinformatics\/btw216","article-title":"ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information","volume":"32","author":"Lachmann","year":"2016","journal-title":"Bioinformatics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/13543784.2019.1605354","article-title":"Targeting transcription factors in multiple myeloma: evolving therapeutic strategies","volume":"28","author":"Li","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"key":"B18","first-page":"504","article-title":"Master regulators used as breast cancer metastasis classifier","volume-title":"Pacific symposium on biocomputing. Pacific symposium on biocomputing","author":"Lim","year":"2009"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1093\/nar\/gky015","article-title":"RGBM: regularized gradient boosting machines for identification of the transcriptional regulators of discrete glioma subtypes","volume":"46","author":"Mall","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/leu.2011.122","article-title":"The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma","volume":"25","author":"Martin","year":"2011","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semcancer.2016.08.005","article-title":"NF-\u03baB dysregulation in multiple myeloma","volume":"39","author":"Matthews","year":"2016","journal-title":"Seminars Cancer Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jcp-2022-208350","article-title":"Gene of the month: ERG","volume":"75","author":"Mullen","year":"2022","journal-title":"J. Clin. Pathol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2020.11.045","article-title":"A modular master regulator landscape controls cancer transcriptional identity","volume":"184","author":"Paull","year":"2021","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: shifting paradigms in drug discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3324\/haematol.2023.282912","article-title":"Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed\/refractory acute myeloid leukemia","volume":"109","author":"Shahswar","year":"2024","journal-title":"Haematologica"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1422478","DOI":"10.3389\/fimmu.2024.1422478","article-title":"Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma","volume":"15","author":"Shi","year":"2024","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"20004","DOI":"10.1073\/pnas.2005052117","article-title":"Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma","volume":"117","author":"Shirazi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1097\/rlu.0000000000004496","article-title":"Unusual extramedullary manifestation in multiple myeloma: bilateral synchronous testicular infiltration","volume":"48","author":"Strauss","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20171697","article-title":"Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis","volume":"38","author":"Tian","year":"2018","journal-title":"Biosci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/art.42944","article-title":"ERG regulates lymphatic vessel specification genes and its deficiency impairs wound healing-associated lymphangiogenesis","volume":"76","author":"Yamashita","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","article-title":"Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma","volume":"98","author":"Zanwar","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1021587","DOI":"10.3389\/fcell.2022.1021587","article-title":"A prognostic model for patients with primary extramedullary multiple myeloma","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1586870\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T05:39:13Z","timestamp":1752644353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1586870\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":35,"alternative-id":["10.3389\/fcell.2025.1586870"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2025.1586870","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"article-number":"1586870"}}